Home › Castration-Resistant Prostatic Cancer › Massachusetts › Boston
Castration-Resistant Prostatic Cancer clinical trials in Boston, MA
5 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 3
- Massachusetts General, Boston
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
RecruitingPhase 3
- Dana Farber Cancer Institute, Boston
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
RecruitingPhase 1
- Dana-Farber Cancer Institute, Boston
Castration-Resistant Prostatic Cancer trials in other cities
- Los Angeles, CA8 studies
- New York City, NY7 studies
- Seattle, WA6 studies
- Houston, TX6 studies
- Philadelphia, PA4 studies
- Queens, NY4 studies
- Pittsburgh, PA4 studies
- Mountain View, CA3 studies
- San Francisco, CA3 studies
- Minneapolis, MN3 studies
- Baltimore, MD3 studies
- St. Louis, MO3 studies
Other studies in Boston
- Breast Cancer111 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.